Sinocelltech Group Limited

As China’s immuno-oncology market adapts to the ever-growing ranks of homegrown PD-1/L1-targeting agents, SinoCellTech has received approval for what will be the 17th product in the sector - but the f

A decade into their quest to conduct successful Phase III clinical trials in the US, Chinese developers of innovative drugs seemed to lose steam in 2022 - but are still clinging to new hope over the u

A decade into their quest to conduct successful Phase III clinical trials in the US, Chinese developers of innovative drugs seemed to lose steam in 2022 – but are still clinging to new hope over the u

A decade into their quest to conduct successful Phase III clinical trials in the US, Chinese developers of innovative drugs seemed to lose steam in 2022 - but are still clinging to new hope over the u